Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

ICD-10 · E28.2

Polycystic ovary syndrome(PCOS)

PCOS is the most common endocrine disorder in women of reproductive age, affecting roughly 8-13% globally. It is characterized by irregular menstrual cycles, excess androgens, and polycystic ovaries. GLP-1 medications are increasingly used off-label for the obesity and insulin-resistance components of PCOS.

Medically reviewed by Dr. Jane Novak, MD, MPH on June 1, 2026

This is general health information, not medical advice. Talk to a licensed clinician about diagnosis and treatment options.

Overview

PCOS combines reproductive (irregular cycles, infertility), metabolic (insulin resistance, weight gain), and dermatologic (acne, hirsutism) features. The exact cause is unknown but involves insulin resistance and elevated androgens. Approximately 60-70% of women with PCOS have insulin resistance regardless of weight. GLP-1 receptor agonists are not FDA-approved specifically for PCOS but are increasingly prescribed off-label for PCOS-associated obesity and insulin resistance. Metformin remains the first-line metabolic treatment. A 2023 meta-analysis in *Reproductive BioMedicine Online* found semaglutide improved menstrual regularity and reduced free androgen index.

Symptoms

Irregular periods
Infertility
Acne and oily skin
Hirsutism (excess hair growth)
Weight gain
Hair thinning
Insulin resistance

Risk factors

Family history of PCOS
Insulin resistance
Obesity
Sedentary lifestyle

Treatment options

Hormonal contraceptives
Metformin
Spironolactone (anti-androgen)
GLP-1 receptor agonists (off-label)
Letrozole/clomiphene for fertility
Lifestyle intervention

GLP-1 evidence for polycystic ovary syndrome

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
GLP-1 therapy improves insulin sensitivity in PCOS Source: Reproductive Biology & Endocrinology, 2023 (opens in a new tab) Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial	BModerate evidence	Small-to-medium RCTs (n<300 each) show improved HOMA-IR; no large definitive trial
GLP-1 weight loss restores ovulatory cycles in some patients Observational + small trial data; ovulation rate ~30-50% higher than controls	BModerate evidence	Observational + small trial data; ovulation rate ~30-50% higher than controls
GLP-1 directly treats hyperandrogenism (acne, hirsutism) Effect appears secondary to weight loss + insulin improvement, not androgen-specific	CLimited evidence	Effect appears secondary to weight loss + insulin improvement, not androgen-specific
GLP-1 is FDA-approved for PCOS No FDA-approved indication for PCOS; use is off-label, weight-driven	FNo evidence	No FDA-approved indication for PCOS; use is off-label, weight-driven

Not sure which medication is right for you? Our quiz matches you with providers based on state, insurance, and budget.

Take the GLP-1 quiz

Common questions readers ask

Do I need to exercise on Wegovy?: Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.
How fast do results show on GLP-1?: Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.
Why am I not losing weight on Wegovy?: Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.
Can I build muscle on a GLP-1?: Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.
Can GLP-1 help with PCOS?: Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.
Does GLP-1 work for type 1 diabetes?: No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

Sources

International evidence-based guideline for PCOS (opens in a new tab) — Monash University / Endocrine Society
GLP-1 receptor agonists in PCOS (opens in a new tab) — Reproductive BioMedicine Online

Was this page helpful?

Polycystic ovary syndrome(PCOS)

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for polycystic ovary syndrome

Related GLP-1 medications

Mounjaro

Wegovy

Ozempic

Common questions readers ask

Sources